1. DIVISION OF PULMONARY, ALLERGY AND RHEUMATOLOGY PRODUCTS (DKKNRBB)

A. Reviews investigational new drugs (INDs) and decides on appropriate action, including approval or disapproval of research plans and protocols, modifications, and restrictions. Develops policies and procedures pertinent to particular aspects of drug investigation.

B. Evaluates new drug applications (NDAs) for safety and effectiveness and(formulates decisions or recommendations regarding approvability in accord with applicable delegations of authority. Develops policies and procedures applicable to the review and evaluation of drugs regulated by the division.

C. Evaluates adequacy of directions for use, warning, and other information in proposed labeling for products regulated by the division.

D. Evaluates and takes appropriate action on recommendations concerning withdrawal of approval of NDAs for drugs regulated by the division.

E. Works collaboratively with the Office of Drug Safety to conduct continuing surveillance and medical evaluation of the labeling, clinical experience, and reports submitted by IND sponsors, by NDA applicants and from other sources.

F. Provides advice and information to other components of the Center and to the Agency on drug products in the areas of pulmonary, allergy and...
rheumatologic drug products with regard to medical and scientific issues, status of processing of drug applications, and appropriate policy, and proposed regulatory actions

G. Develops, in coordination with other Agency components, guidance for staff, sponsors and the public that describes the Agency’s interpretation of or policy on regulatory issues that involve the division

2. AUTHORITY AND EFFECTIVE DATE

The functional statements for this Division were approved by the Secretary of the Department of Health and Human Services on July 8, 2011.

<table>
<thead>
<tr>
<th>STATUS (I, R, C)</th>
<th>DATE APPROVED</th>
<th>LOCATION OF CHANGE HISTORY</th>
<th>CONTACT</th>
<th>APPROVING OFFICIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial</td>
<td>05/01/2005</td>
<td>N/a</td>
<td>OC/00/OM/OMP</td>
<td>Acting Director, Center for Drug Evaluation and Research</td>
</tr>
<tr>
<td>Revision</td>
<td>01/12/2010</td>
<td>N/a</td>
<td>OC/0A/OM/OMP</td>
<td>Commissioner of Food and Drugs</td>
</tr>
<tr>
<td>Revision</td>
<td>07/08/2011</td>
<td>N/a</td>
<td>CDER/OM</td>
<td>Secretary of the Department of Health and Human Services</td>
</tr>
</tbody>
</table>
The following is the Food and Drug Administration, Office of Medical Products and Tobacco, Center for Drug Evaluation and Research, Office of New Drugs, Office of Drug Evaluation II, Division of Pulmonary, Allergy and Rheumatology Products organization structure depicting all the organizational structures reporting to the Director.

OFFICE OF THE DIRECTOR